Tradestie Institutional Equity Comparison Engine

SRPT vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRPT Overall Edge

SRPT Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, SRPT trades at 10.8x Forward P/E with -0.4% operating margin (-4.5% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SRPT
SRPT 10.8x vs FDMT N/M Fwd P/E
Growth & Margin Winner SRPT
Op Margin -0.4% vs -222.7% ยท YoY -4.5% vs +4505.6%
Momentum & Technical Winner FDMT
1Y -15.0% vs +13.3% ยท 52W Pos 5% vs 47%
Options & Structure Winner SRPT
BREAKDOWN (7th %ile IV) vs BREAKDOWN (10th %ile IV)
SRPT NASDAQ
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.14
-5.76% 1D
Market Cap $1.7B
1M Return -11.44%
1Y Return -15.02%
Forward P/E 10.8x
Unified AI Score
37.8 / 100 SELL
Tech 32.0 Fund 51.0 Flow 71.0 Mom 60.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRPT -15.02% FDMT +13.33% Spread: +28.35 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRPT Revenue FDMT Revenue SRPT Op. Margin FDMT Op. Margin Margin Edge
FY2018 $300M N/A -114.1% N/A SRPT
FY2019 $380M $10M -185.3% -729.4% SRPT
FY2020 $460M $10M -123.8% -424.0% SRPT
FY2021 $610M $20M -75.1% -395.5% SRPT
FY2022 $840M $0M -63.5% -3516.5% SRPT
FY2023 $1.14B $20M -23.4% -544.6% SRPT
FY2024 $1.79B $0M 12.2% -507678.4% SRPT
FY2025 $1.86B $90M -37.5% -187.2% SRPT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRPT (6) vs FDMT (3)
Institutional Metric SRPT FDMT Criterion Row Winner
Market Capitalization Scale $1.7B $669.3M Larger Scale SRPT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation 10.8x N/M Lower Multiple SRPT
Revenue Growth (YoY) Growth -4.5% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability -0.4% -222.7% Higher Margin SRPT
Net Profit Margin Profitability -5.9% -208.6% Higher Margin SRPT
Return on Equity (ROE) Capital Efficiency -8.1% -56.7% Higher ROE SRPT
52-Week Range Position Momentum 5% ($15โ€“$25) 47% ($7โ€“$17) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.47ฮฒ ยท 58% Vol 1.89ฮฒ ยท 90% Vol Lower Realized Risk SRPT
Unified Institutional Score Composite Signal 37.8 / 100 (SELL) 51.3 / 100 (HOLD) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRPT vs FDMT Buy Guide
SRPT BREAKDOWN
52d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live SRPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRPT nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.